Reuters logo
BRIEF-Ose immunotherapeutics signs license agreement with Servier
December 28, 2016 / 6:13 AM / 9 months ago

BRIEF-Ose immunotherapeutics signs license agreement with Servier

Dec 28 (Reuters) - Ose Immunotherapeutics :

* Grants Servier license option on exclusive worldwide rights for development and commercialization of Effi-7

* Signs license option agreement with Servier to develop and commercialize product Effi-7

* Becomes eligible to receive up to 272 million ($284.92 million) including an upfront payment of 10.25 million and additional payments of 30 million upon the exercise of a two-steps option license

* Further license payments from Servier linked to achievement of clinical development and registration in multiple indications, as well as to sales milestones with double-digit royalties on sales Source text for Eikon: Further company coverage: ($1 = 0.9547 euros) (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below